The ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY, published by the Allergy Immunology Society of Thailand, is a pivotal platform for disseminating high-quality research in the fields of allergy and immunology. Established in 1983, this journal has consistently evolved to address the pressing challenges and advancements in these dynamic disciplines, contributing significantly to the global scientific community's understanding of immunological disorders. With a category ranking of Q3 in Immunology and Allergy, and Q2 in Medicine (miscellaneous) for 2023, the journal stands at the forefront of impactful research, engaging with a diverse audience of researchers, clinicians, and students alike. Although it operates on a non-open access model, its rigorous peer-review process ensures that published articles meet the highest academic standards. Located in Bangkok, Thailand, the journal connects researchers across the Asia-Pacific region, fostering collaboration and innovation to enhance patient care in the realm of allergy and immunology.

BMC Pulmonary Medicine is a leading open access journal dedicated to the field of pulmonary and respiratory medicine, published by BMC since its inception in 2001. With an ISSN of 1471-2466, this journal plays a pivotal role in advancing knowledge and research dissemination in its field, maintaining a prominent position with a 2023 Scopus ranking of #65 out of 155 journals, placing it within the 58th percentile of the category. Based in the United Kingdom, it operates under a collaborative mission to provide unrestricted access to vital research, contributing to the global understanding of respiratory health issues. The journal is recognized for its commitment to high-quality, peer-reviewed research, as evidenced by its Q2 category designation in Pulmonary and Respiratory Medicine. BMC Pulmonary Medicine aims to foster innovation and scholarship among researchers, professionals, and students, making it an indispensable resource for anyone engaged in pulmonary research and practice. The journal, accessible to everyone, enables the dissemination of impactful research that can influence clinical practice and policy worldwide.

Gastrointestinal Disorders is a prominent open-access journal published by MDPI, based in Switzerland, that focuses on the latest research and innovations in the fields of gastroenterology, hepatology, and immunology. Since its inception in 2019, the journal has provided a vital platform for researchers and professionals to disseminate their findings, engaging with a global audience keen on advancing knowledge in gastrointestinal health. With a dedicated commitment to high-quality, peer-reviewed articles, Gastrointestinal Disorders has gained recognition in 2023, achieving Q3 status in gastroenterology and notable rankings in several other categories, including a respectable position in the quartiles for hepatology, immunology, and oncology. Despite its recent establishment, the journal has quickly become a valuable resource, facilitating open access to critical insights in the study of gastrointestinal diseases and their management, ensuring that emerging research is readily available to inform clinical practice and educate future professionals.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, published by MOSBY-ELSEVIER, stands as a leading peer-reviewed journal dedicated to advancing the understanding of allergies and immunological conditions. With a notable impact factor and a prominent stature in the academic community, it ranks in the Q1 category for both Immunology and Allergy in 2023, reflecting its significance and high citation rates among researchers. Since its establishment in 1963, the journal has fostered scientific discourse and innovation in the field, positioning itself as an essential resource for both seasoned professionals and emerging scholars. The Scopus rankings underscore its influence, being ranked 12th out of 233 in Immunology and Allergy and 15th out of 236 in Immunology and Microbiology, placing it in the top centile of both categories. The journal aims to disseminate cutting-edge research, reviews, and clinical studies that deepen our understanding of allergic diseases and enhance patient care. While not an open access journal, it provides institutions and individuals with opportunities to stay informed on crucial advancements in the immunological sciences.

The Revue Francaise d'Allergologie, an esteemed publication in the field of Immunology and Allergy, is published by ELSEVIER MASSON, CORP OFF in France. This journal plays a pivotal role in disseminating significant findings and advancements in allergy research and immunotherapy, reflecting the latest trends and challenges in these rapidly evolving areas. As part of its commitment to scholarly rigor, the journal encompasses a wide range of topics pertinent to allergology, aiming to bridge the gap between clinical practice and academic research. Although currently not listed as open access, it provides critical insights essential for researchers, professionals, and students alike, ensuring the advancement of knowledge and therapeutic strategies in allergy and immunology. With its impact factor and positioning in the Q4 category, it serves as a valuable resource, aiding in the education and development of future leaders in the field. The Revue Francaise d'Allergologie continues to be a vital platform for the exchange of innovative ideas and findings from 2009 to the present.

Tuberculosis and Respiratory Diseases is a leading open-access journal published by THE KOREAN ACADEMY OF TUBERCULOSIS & RESPIRATORY DISEASES, dedicated to disseminating knowledge in the fields of infectious diseases and pulmonary medicine. Since its inception in 1980, the journal has undergone significant growth, currently recognized in the elite Q2 category for both Infectious Diseases and Pulmonary and Respiratory Medicine as of 2023. With an impact factor reflecting its esteemed position—ranked 52nd in its category—it serves as a vital resource for researchers and healthcare professionals seeking cutting-edge insights, studies, and advancements in the management and treatment of respiratory diseases, particularly tuberculosis. The journal is committed to providing open access to its content since 2013, ensuring that critical research is available to scholars worldwide, fostering collaboration and innovation in the global fight against respiratory illnesses.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY is a premier peer-reviewed journal published by Elsevier Science Inc, dedicated to advancing the fields of allergy, asthma, and immunology. With its roots dating back to 1995 and with a focus on high-impact research, this journal has established itself as a leading platform for the dissemination of original research, reviews, and clinical studies within these critical areas. The journal boasts an impressive impact factor, supporting its Q2 ranking in both Immunology and Allergy, as well as in Pulmonary and Respiratory Medicine, indicating its significant contribution to the scientific community. Although it does not currently offer open access options, its comprehensive coverage and rigorous peer-review process ensure that published articles are of the highest quality, making it an invaluable resource for researchers, clinicians, and students alike. The Scopus rankings reflect its esteemed position in the academic landscape, providing professionals with access to cutting-edge developments and insights into the management and treatment of allergic and respiratory conditions.

Current Opinion in Allergy and Clinical Immunology, published by Lippincott Williams & Wilkins, is a pivotal journal that serves as a key resource for professionals in the fields of immunology and allergy. With an ISSN of 1528-4050 and an E-ISSN of 1473-6322, this journal presents cutting-edge reviews of the latest research findings, methodologies, and therapeutic approaches in the management of allergic and immunological disorders. With a Q3 category ranking in both Immunology and Allergy for 2023, and a Scopus rank of #103 in Immunology and Allergy, it reflects a solid position within the scientific community. Operating in the highly dynamic fields of immunology and clinical practice since its inception in 2001, the journal aims to harmonize emerging research trends with clinical applications to enhance patient outcomes. Although it does not currently offer Open Access options, the journal's substantial impact factor attests to its significance as a scholarly resource. By disseminating high-quality reviews and expert opinions, Current Opinion in Allergy and Clinical Immunology continues to foster knowledge advancement and professional development among researchers, practitioners, and students alike.

The Journal of Allergy and Clinical Immunology-In Practice, published by ELSEVIER, stands as a leading platform in the field of allergy and immunology, specifically tailored for practitioners and researchers. With an impressive 2023 Q1 ranking in both the Immunology and Allergy categories, this journal demonstrates a significant impact within the academic community, evidenced by its Scopus rank #41 out of 233 and an impressive percentile rank of 82. The journal focuses on providing advanced studies, clinical findings, and innovative treatment methodologies that address current challenges in allergy and immunology, making it a vital resource for professionals in these fields. With a comprehensive coverage of relevant topics from 2013 to 2024, the journal continues to evolve alongside emerging trends and developments in clinical practice, fostering an environment conducive to scholarly research and application. Although it currently does not offer open access, authors and readers can access a wealth of information and contribute to ongoing dialogues through its robust publication platform.

Alergia Astma Immunologia is a dedicated journal focusing on the interdisciplinary fields of immunology and respiratory medicine, published by the Asthma and Allergy Patients Support Organization in Poland. With a commitment to advancing research and sharing knowledge, this journal serves as a platform for scholars and practitioners to discuss critical issues and recent advances in allergy, asthma, and immunological disorders. Despite being in Category Quartiles Q4 for both Immunology and Allergy and Pulmonary and Respiratory Medicine, its importance is highlighted by its continuous publication since 2000, providing a historical perspective on evolving scientific insights. Researchers and clinicians alike benefit from accessing novel findings and case studies that contribute to improved patient outcomes and innovative therapeutic strategies. While the journal currently offers limited open access, its commitment to providing high-quality, peer-reviewed content ensures its relevance in the academic discourse within these vital areas of health science. The journal aims to foster collaboration, stimulate research interest, and promote evidence-based practices within the professional community.